Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash & Equivalents (2019 - 2025)

Keros Therapeutics filings provide 7 years of Cash & Equivalents readings, the most recent being $287.4 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 48.67% to $287.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $287.4 million, a 48.67% decrease, with the full-year FY2025 number at $287.4 million, down 48.67% from a year prior.
  • Cash & Equivalents hit $287.4 million in Q4 2025 for Keros Therapeutics, down from $693.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $720.5 million in Q1 2025 to a low of $215.6 million in Q2 2022.
  • Median Cash & Equivalents over the past 5 years was $305.0 million (2023), compared with a mean of $376.5 million.
  • Biggest five-year swings in Cash & Equivalents: soared 368.11% in 2021 and later plummeted 48.67% in 2025.
  • Keros Therapeutics' Cash & Equivalents stood at $230.0 million in 2021, then grew by 21.3% to $279.0 million in 2022, then increased by 18.67% to $331.1 million in 2023, then surged by 69.09% to $559.9 million in 2024, then plummeted by 48.67% to $287.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $287.4 million (Q4 2025), $693.5 million (Q3 2025), and $690.2 million (Q2 2025) per Business Quant data.